LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Kura Oncology, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERKURA
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / KURA COVERAGE

What’s moving Kura Oncology, Inc. now

Current reporting with the operating signal separated from the noise.

01
Seeking Alpha

Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma - Slideshow (NASDAQ:KURA) 2026-07-29

The story matters when it changes Kura Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest KURA filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-12 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-04 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-05 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-29 · Period 2026-07-24SEC ↗8-KMaterial company eventFiled 2026-06-04 · Period 2026-06-04SEC ↗8-KMaterial company eventFiled 2026-05-12 · Period 2026-05-12SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-10 · Period 2026-06-04SEC ↗4Official SEC filingFiled 2026-06-22 · Period 2026-06-18SEC ↗
EARNINGS / QUARTERLY TRACKER

Kura Oncology, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.